NEW YORK (GenomeWeb) – Integrated DNA Technologies announced today that it has acquired the oligonucleotide manufacturing business of Australian molecular and cell biology company GeneWorks.
Specific terms of the deal were not disclosed.
The acquisition, which was completed through IDT's Singapore subsidiary, expands the company's reach in the Asia-Pacific region, and follows the recent establishment of IDT offices in Japan and Korea.
IDT offers a broad range of custom, synthetic nucleic acids for molecular biology applications, including qPCR, sequencing, synthetic biology, and functional genomics.
"With this acquisition, we are furthering our goal of making our world-class products and services more easily accessible to scientists around the world," IDT Founder and CEO Joseph Walder said in a statement. "We look forward to availing GeneWorks' customers of our unrivaled manufacturing capabilities, design expertise, and fast turnaround times."
Indeed, this is the latest in a string of similar deals for IDT. In December 2015, the firm acquired the oligonucleotide business of Singapore's AITbiotech, noting the expansion of its customer base in Southeast Asia. And in June 2016, IDT acquired San Diego-based oligonucleotide synthesis firm ValueGene.